Skip to main content
. 2022 Jun 14;10:893387. doi: 10.3389/fpubh.2022.893387

Figure 2.

Figure 2

(A) Kaplan–Meier curve of the overall survival from the KEYNOTE-590 trial. (B) Simulate overall survival curve for pembrolizumab group and chemotherapy group. (C) Kaplan–Meier curve of progression-free survival from the KEYNOTE-590 trial. (D) Simulate progression-free survival curve for pembrolizumab group and chemotherapy group.